Strata Critical Medical (SRTA)
Coordinates organ-transport logistics and surgical recovery services for U.S. transplant centers.
Something off on this page? Send us feedback.
Runs a two-segment medical-logistics business — air and ground transport of donor organs for U.S. transplant centers under the Trinity brand, and surgical organ recovery plus normothermic perfusion under the Keystone brand — built on a network of contracted charter operators rather than a large owned fleet.
Coordinates time-critical logistics and clinical services for organ transplantation across the United States, running a Logistics segment marketed as Trinity and a Clinical segment marketed as Keystone.
Trinity arranges air and ground transport of donor organs and surgical teams for transplant centers and organ procurement organizations; Keystone performs surgical organ recovery and normothermic regional perfusion that extends how long a donated organ stays viable, plus perfusion staffing for hospitals outside the transplant pipeline.
Most transport runs through contracted third-party charter operators rather than a large owned fleet, and growth has come mainly through acquiring established commercial partners rather than building services from scratch.
Originally an urban air-mobility operator founded in 2014, the company sold its passenger business and narrowed to organ logistics and recovery in 2025. Demand tracks national policy on organ donation and allocation across U.S. transplant centers.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $22.8M · Total debt $4.3M · Total assets $332.7M · Shareholders' equity $279.3M
- Revenue
- $72.5M
- Operating income
- −$5.4M
- Net income
- −$10.5M
No dividends on record.
| Insiders | 30.87% | 27.31M shares | |
|---|---|---|---|
| 15 holders · as of Sep 10, 2026 | |||
| Strategic holders | 10.61% | 9.38M shares | |
| 2 holders · as of Jan 21, 2026 | |||
| Other | 58.52% | 51.77M shares | |
| remainder | |||
88.47M company shares as of Sep 22, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Robert S. Wiesenthal1Insiderdirector | 17.45% | 10.11M · 5.33M | filed May 17, 2021 |
ARK Investment Management LLCInstitution | 8.43% | 7.46M | filed Apr 30, 2026 |
Third Point LLCStrategic | 5.65% | 5.00M | filed Nov 14, 2025 |
Northern Right Capital Management, L.P.Institution | 4.97% | 4.40M | filed Jun 17, 2026 |
BlackRock, Inc.Strategic | 4.96% | 4.38M | filed Jan 21, 2026 |
- Robert S. Wiesenthal's transaction reports restate only vehicles that traded; the 2021 ownership statement (10.11M) is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 10, 2026 | Reginald Love | director | −5,091 | $5.75 |
| Jun 8, 2026 | Scott M. Wunsch | officer: CEO, Logistics | −5,550 | $5.87 |
| Jun 8, 2026 | Melissa M. Tomkiel | director, officer: Co-CEO and General Counsel | −29,730 | $5.87 |
| Jun 8, 2026 | Amir Cohen | officer: Chief Accounting Officer | −4,655 | $5.87 |
| Jun 8, 2026 | William A. Heyburn | director, officer: Co-CEO and CFO | −31,671 | $5.87 |
- TransMedics Group
Device maker running an end-to-end organ retrieval and logistics service
- LivaNova
UK medtech; global leader in heart-lung machines for cardiac surgery
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Strata Critical Medical | $5.38 | −0.39% | $467.2M | 10.8 | 89.6 | 1.8 | +2.4% |
| TransMedics Group | $88.53 | +1.42% | $3.02B | 22.6 | 48.3 | 4.5 | +20.7% |
| LivaNova | $78.72 | +0.71% | $4.29B | 23.1 | 17.9 | 2.9 | +10.8% |
| Median | 22.8 | 33.1 | 3.7 | +15.8% |